Lyophilized Arsenic Trioxide Composition for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional arsenic trioxide treatments for hematological malignancies require daily intravenous administration, which is inconvenient, risky, and expensive, and there is no FDA-approved oral formulation, due to the insolubility and lack of bioavailability of As2O3.
Innovation Solution
A lyophilized composition comprising arsenic trioxide is developed, solubilized and lyophilized to enhance bioavailability, allowing oral administration in the form of capsules or tablets, with a method involving alkalization, acidification, and lyophilization steps to improve solubility and surface area.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravenous administration of arsenic trioxide is used, then cancer treatment efficacy is achieved, but administration convenience deteriorates and treatment cost increases
Solution Approach 1:
The patent changes the physical and chemical parameters of arsenic trioxide by creating a lyophilized formulation with specific particle size (D90 ≤ 10 microns) and solubility characteristics. This transformation allows the drug to be administered orally while maintaining the therapeutic efficacy previously achieved only through intravenous administration.
Solution Approach 2:
The patent creates a composite pharmaceutical formulation consisting of arsenic trioxide combined with specific excipients and adjuvants. This composite structure improves the solubility and bioavailability of arsenic trioxide, enabling effective oral administration while maintaining cancer treatment efficacy.
2Reliability
If intravenous administration of arsenic trioxide is used, then cancer treatment efficacy is achieved, but treatment cost increases
Solution Approach 1:
The patent transforms arsenic trioxide into a lyophilized oral formulation with optimized particle size and solubility parameters. This change enables administration in a less resource-intensive manner (oral vs. intravenous), reducing hospitalization requirements and associated costs while maintaining treatment efficacy.
Solution Approach 2:
The patent develops a stable lyophilized formulation that can be stored and administered as discrete oral doses. This approach eliminates the need for expensive intravenous infusion equipment and hospital infrastructure, making treatment more cost-effective while maintaining efficacy.
3Ease of operation
If oral formulation of arsenic trioxide is developed, then administration convenience is improved, but solubility and bioavailability worsen
Solution Approach 1:
The patent fundamentally changes the solubility parameters of arsenic trioxide through lyophilization and particle size reduction (D90 ≤ 10 microns). These parameter changes increase the surface area and dissolution rate, achieving oral bioavailability comparable to intravenous administration despite the poor inherent solubility of arsenic trioxide.
Solution Approach 2:
The patent introduces specific excipients and adjuvants as intermediaries that facilitate the solubility and absorption of arsenic trioxide in the gastrointestinal tract. These substances act as mediators between the poorly soluble drug and the biological system, enabling effective oral delivery.
4Ease of operation
If arsenic trioxide is administered orally without formulation optimization, then administration convenience is improved, but treatment reliability deteriorates
Solution Approach 1:
The patent optimizes critical parameters including particle size (D90 ≤ 10 microns), solubility, and formulation composition to ensure reliable oral delivery. These parameter changes maintain treatment efficacy while enabling convenient oral administration, achieving both reliability and ease of operation.
Solution Approach 2:
The patent performs preliminary formulation development and optimization before clinical use, creating a stable lyophilized product with validated bioavailability. This preliminary action ensures that when the drug is administered orally, it achieves reliable therapeutic outcomes without requiring further optimization during treatment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lyophilized composition achieves systemic bioavailability comparable to intravenous administration, with improved solubility and oral bioavailability, providing a convenient and cost-effective treatment option for hematological malignancies.
Implementation Method 1
A lyophilized composition comprising arsenic trioxide is developed, solubilized and lyophilized to enhance bioavailability
Implementation Method 2
A lyophilized composition comprising arsenic trioxide is developed, solubilized and lyophilized to enhance bioavailability
Data Source
AI summary
Described herein are methods of treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in need thereof. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas, and solid tumors including glioblastoma multiforme and breast cancer. Also described herein are oral pharmaceutical formulations comprising lyophilized compositions comprising arsenic and methods for lyophilizing arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and treating a subject with malignancies using the oral formulation.